Peptide Association LLC is a for-profit company. We receive compensation from the clinical providers listed on this site. We are not an accrediting body, a licensing board, or a government-affiliated organization. See exactly how we make money.
Angiotensin (1-7)
Overview
Angiotensin (1-7) is a seven-amino acid peptide component of the renin-angiotensin system formed through cleavage of angiotensin II by ACE2 or from angiotensin I by endopeptidases. It binds to the Mas receptor to produce vasodilation, anti-proliferative, anti-fibrotic, and anti-inflammatory effects that generally oppose the actions of angiotensin II.
Mechanism of Action
This counter-regulatory arm of the renin-angiotensin system represents a therapeutic target in hypertension, heart failure, and renal disease.
Research Summary & Key Findings
Preclinical studies have demonstrated that angiotensin (1-7) reduces blood pressure, attenuates cardiac remodeling, and improves endothelial function in animal models of cardiovascular disease. Clinical development has been limited by the peptide's short half-life, though modified analogues and oral formulations are under investigation without published phase 3 trial results.
Clinical Status
Angiotensin (1-7) is in the investigational stage. While preclinical and early-phase data exist, it has not received regulatory approval for clinical use in the United States.
Administration Routes
References
Primary literature
- PubMed: "Angiotensin"
Peer-reviewed literature indexed by the National Library of Medicine.
- ClinicalTrials.gov: "Angiotensin"
Registered interventional and observational studies, including status and phase.
- PubChem: "Angiotensin"
Chemical structure, molecular properties, and bioactivity data.
Study-level citations for this compound are being verified against the primary sources before publication. The database queries above return the current indexed literature in the meantime.
Related Peptides in Cardiovascular
Eptifibatide (Integrilin)
FDA ApprovedA synthetic cyclic heptapeptide modeled after the KGD (Lys-Gly-Asp) disintegrin sequence found in the venom of the south...
View detailsNesiritide (Natrecor)
FDA ApprovedA recombinant form of human B-type natriuretic peptide (BNP), a 32-amino acid peptide naturally produced by ventricular ...
View detailsAngiotensin II (Giapreza)
FDA ApprovedA synthetic form of the endogenous octapeptide angiotensin II, the primary effector of the renin-angiotensin system. Ang...
View detailsSerelaxin (Relaxin-2)
InvestigationalSerelaxin is a recombinant form of human relaxin-2, a naturally occurring peptide hormone composed of two chains linked ...
View detailsNo lawful pathway today
Angiotensin (1-7) is not FDA-approved and does not currently have a lawful prescription or compounding pathway in the United States, so there is nothing for us to sell you here and no consultation to book. That can change: eight peptides moved back to a lawful pathway in February 2026.
Tell me if the status changes
One email, only if this compound's regulatory standing actually moves. Not a newsletter, not a sales sequence.
Join the Association
Access exclusive peptide protocols, provider resources, and community support.
List Your PracticeDisclaimer: This information is provided for educational and research purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide therapy. The Peptide Association does not endorse or recommend any specific treatment protocol. See our editorial policy for how this content is produced and reviewed.